Table 6

Results of univariate analysis of survival after salvage chemoradiotherapy
  Factors No. of patients Median survival time (months) 6-month survival (%) 1-year survival (%) 2-year survival (%) p-value
All patients 30 8.8 77 33 26
Age
  < 65 14 8.1 79 29 14
  ≥ 65 16 9.2 75 38 38 0.2
Gender
  Male 16 8.1 75 31 25
  Female 14 9.2 79 36 29 0.6
Karnofsky performance status
  ≥ 80 28 9.1 79 36 28
  < 80 2 4.8 50 0 0 0.03
Primary tumor location
  Head 15 9.4 93 40 33
  Body / tail 15 8.5 60 27 18 0.5
Number of regimens of primary chemotherapy
  1 25 9.4 80 40 32
  2 5 6.1 60 0 0 0.006
Best response to primary chemotherapy
  PR 9 9.2 89 33 33
  SD or PD 21 8.5 71 33 24 0.6
Pre-chemoradiotherapy tumor diameter (cm)
  ≤ 4 12 10.8 83 50 50
  > 4 18 8.5 72 22 0 0.04
Pre-chemoradiotherapy serum CA19-9 level (U/ml)
  ≤ 1,000 29 10.8 90 47 42
  > 1,000 11 6.4 54 9 0 0.002
Local progression before starting chemoradiotherapy
  Absent 4 NA 80 60 60
  Present 26 8.8 76 28 19 0.15
Time from the start of primary chemotherapy to chemoradiotherapy
  ≤ 6 months 12 8.5 75 33 25
  > 6 months 18 8.8 78 33 28 0.9
Combined chemoradiotherapy agents
 5-FU 14 7.2 64 21 14
 S-1 16 9.9 88 44 37 0.09

PR partial response, SD stable disease, PD progressive disease, NA not available.

Mayahara et al.

Mayahara et al. BMC Cancer 2012 12:609   doi:10.1186/1471-2407-12-609

Open Data